SAN MATEO, Calif., Sept. 25, 2020 /PRNewswire/ — Rakuten Medical Inc. is proud to announce that its wholly owned subsidiary Rakuten Medical Japan K.K. has received marketing approval in Japan from the Ministry of Health, Labour and Welfare for Akalux® IV Infusion 250mg (cetuximab sarotalocan sodium) to treat unresectable locally advanced or recurrent head and neck cancer.  BioBlade® Laser System, the medical device used in the combination with Akalux, was also approved on September 2^nd. Read more…